Extension of PBS listing for cabozantinib

Cabozantinib (Cabometyx) will be available on the PBS from 1 July 2021 as a first line treatment for stage IV clear cell variant renal cell carcinoma (RCC). The once daily oral tyrosine kinase inhibitor has been available as a second line treatment for patients with advanced RCC since 2018. At its November 2020 meeting, the ...

Already a member?

Login to keep reading.

© 2022 the limbic